Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study

scientific article

Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/S1470-2045(17)30111-0
P8608Fatcat IDrelease_v66ojm2h3vf27fr3hvdfiabcai
P698PubMed publication ID28343975

P50authorEric Van CutsemQ37068027
Hyun Cheol ChungQ59647646
Jaffer AjaniQ64913003
Atsushi OhtsuQ115365827
P2093author name stringGail D Lewis Phillips
Yoon-Koo Kang
Betsy L Althaus
Gyorgy Bodoky
Hugo Castro
Kohei Shitara
Manish A Shah
Marie-Laurence Harle-Yge
Peter C Thuss-Patience
Tina van der Horst
Wasat Mansoor
P2860cites workTrastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialQ27851578
Trastuzumab emtansine for HER2-positive advanced breast cancerQ27851917
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trialQ27853001
Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III studyQ27853010
HER2 testing in gastric cancer: a practical approachQ28256814
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trialQ29620687
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trialQ29620917
HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancerQ30837184
Chemotherapy vs supportive care alone for relapsed gastric, gastroesophageal junction, and oesophageal adenocarcinoma: a meta-analysis of patient-level dataQ31046335
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trialsQ33576276
Trastuzumab emtansine: mechanisms of action and drug resistanceQ33759627
Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugateQ34880994
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical ModelsQ38790625
Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatmentsQ38913644
Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancerQ39664583
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).Q42608504
An adaptive seamless phase II/III design for oncology trials with subpopulation selection using correlated survival endpointsQ44262116
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 400Q44754243
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancerQ44819759
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer.Q45928785
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trialQ48117450
Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone.Q53384216
Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.Q53599393
Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.Q54402875
A Phase II trial of vinorelbine in patients with advanced gastroesophageal adenocarcinomaQ79733212
P433issue5
P921main subjectadenocarcinomaQ356033
trastuzumabQ412616
P304page(s)640-653
P577publication date2017-03-23
P1433published inLancet Oncology CommissionQ13747613
P1476titleTrastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
P478volume18

Reverse Query: null

Search more.